SPECIFICATION AMENDMENTS

Replace the paragraph beginning at page 9, line 10 with:

In one embodiment, the cancer peptide of the present invention comprises the amino acid sequence:

MQAEGRGTGG STGDADGPGG
PGIPDGPGGN AGGPGEAGAT
GGPRGPRGAGA ARASGPGGGA
PRGPHGGAAS GLNGCCRCGA
RGPESRLLEF YLAMPFATPM
EAELARRSLA QDAPPLPVPG
VLLKEFTVSG NILTIRLTAA
DHRQLQLSIS SCLQQLSLLM
WITQCFLPVF LAQPPSGQRR (SEQ. ID NO: 4) and cancer epitopes, fragments, or derivatives thereof. Also encompassed in the ambit of the invention are cancer peptides or portions thereof that share partial sequence homology with SEQ. ID NO: 4. By partial amino acid sequence homology is meant a peptide having at least 85% sequence homology with SEQ. ID NO: 4, preferably at least 95% sequence homology or greater and has the biological function of stimulating cancer antigen specific T lymphocytes. Mammalian homologs are included in the ambit of the invention including but not limited to primate and murine homologs.